CN109134362B - 一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法 - Google Patents

一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法 Download PDF

Info

Publication number
CN109134362B
CN109134362B CN201811145402.5A CN201811145402A CN109134362B CN 109134362 B CN109134362 B CN 109134362B CN 201811145402 A CN201811145402 A CN 201811145402A CN 109134362 B CN109134362 B CN 109134362B
Authority
CN
China
Prior art keywords
formula
group
nitrogen
molar amount
containing heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811145402.5A
Other languages
English (en)
Other versions
CN109134362A (zh
Inventor
傅尧
王佳鑫
尚睿
吴雅楠
付明臣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Science and Technology of China USTC
Original Assignee
University of Science and Technology of China USTC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Science and Technology of China USTC filed Critical University of Science and Technology of China USTC
Priority to CN201811145402.5A priority Critical patent/CN109134362B/zh
Publication of CN109134362A publication Critical patent/CN109134362A/zh
Priority to PCT/CN2019/106182 priority patent/WO2020063399A1/zh
Application granted granted Critical
Publication of CN109134362B publication Critical patent/CN109134362B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/10Aza-phenanthrenes
    • C07D221/12Phenanthridines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

本发明提供的一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法。在简单的碘盐、膦配体和有机溶剂存在的条件下,通过光照实现活性羧酸酯脱羧,并与含氮杂环化合物发生minisci反应引入氮杂环。本发明提供的方法利用光催化,在室温下实现高效催化转化,反应条件温和,操作简单;与之前报道的传统方法相比,该方法避免了贵金属催化剂的使用,符合发展绿色环境友好化学的要求,底物范围广、官能团兼容性好;且该方法可以成功应用于克级规模的放大实验,反应的转化率高,具有工业合成价值前景。

Description

一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法
技术领域
本发明涉及化合物合成领域,具体涉及一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法。
背景技术
芳香杂环化合物是药物化学领域中及其重要的结构单元,通过选择性催化芳香杂环官能团化是发现新药的重要手段之一。实现芳香杂环的官能团化的主要方法是已知的Minisci反应,如已经报道的有 Photoredox/
Figure GDA0002414471660000011
Acid Co-Catalysis EnablingDecarboxylative Coupling of Amino Acid and Peptide Redox-Active Esters withN- Heteroarenes,Wan-Min Cheng,Rui Shang,and Yao Fu,ACS Catal.2017, 7,907-911;Photoredox-Catalysed Decarboxylative Alkylation of N-Heteroarenes with N-(Acyloxy)phthalimides,Wan-Min Cheng,Rui Shang,Ming-Chen Fu,and Yao Fu,Chem.Eur.J.2017,23,2537-2541。然而这些已经报道的方法中往往需要加入贵金属铱催化剂,在后期分离的过程中很难避免贵金属的残留。
发明内容
为解决现有技术中贵金属催化剂比如铱的使用,不仅由于铱价格昂贵而导致生产成本增加而且容易残留在所得产品中的问题,本发明提供了一种光引发非金属催化活性羧酸酯脱羧引入氮杂环的方法,不需要加入金属催化剂,且反应条件温和,对官能团兼容性较好。
为了解决上述技术问题,本发明的技术方案为如下方面:
<1>.一种光诱导活性羧酸酯脱羧引入氮杂环的方法,所述方法包括以下步骤:
在简单的碘盐、膦配体、酸以及有机溶剂存在的条件下,通过光照实现式1含氮杂环化合物与式2化合物反应得到具有式3结构的化合物:
Figure GDA0002414471660000021
其中:
式1的含氮杂环化合物包括被各种取代基取代或不被取代的喹啉、异喹啉、烟酸或菲啶,并且所述各种取代基为C1-C30烷基、C6-C30芳基、卤素、甲基醚或酯基;
式2和式3中的R为不含官能团的C1-C30烷基、含官能团的C1-C30 烷基、C6-C30芳基或C5-C30杂芳基,所述官能团为选自卤素、酯基、醚基、酰基、磺酰基、巯基和氨基中的至少一种。
<2>.根据上述方法,其中,所述式2化合物和式1含氮杂环化合物的摩尔比为1.0-3.0。
<3>.根据上述方法,其中,所述简单的碘盐选自碘化钠、碘化钾以及碘化锂中的至少一种,并且碘盐的摩尔用量为所述含氮杂环化合物摩尔用量的5%-50%。
<4>.根据上述方法,其中,所述的膦配体选自三苯基膦、三(4- 甲氧基苯基)膦、三(4-氟苯基)膦、三环己基膦、2-二苯基膦-联苯、 4,5-双二苯基膦-9,9-二甲基氧杂蒽以及双(2-二苯基磷苯基)醚中的至少一种。
<5>.根据上述方法,其中,膦配体的摩尔用量为所述式1含氮杂环化合物的摩尔用量的5%-50%。
<6>.根据上述方法,其特征在于,所述的酸为三氟乙酸和(R)- 联萘酚磷酸酯的一种,且当采用三氟乙酸时,其摩尔用量为所述式1 含氮杂环化合物的摩尔用量的50%-150%;当采用(R)-联萘酚磷酸酯时,其摩尔用量为所述式1含氮杂环化合物的摩尔用量的5%-50%。
<7>.根据上述方法,其中,所述光源的波长范围为365nm到500 nm之间,照射时间为4小时至24小时。
<8>.根据上述方法,其中,所述有机溶剂选自N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、乙腈、四氢呋喃、三氟甲苯、甲苯、丙酮、二氯甲烷和乙酸乙酯中的至少一种。
<9>.根据上述方法,其中,所述式1化合物选自如下结构的化合物中的至少一种:
Figure GDA0002414471660000031
其中ph表示苯基,Br表示溴,而OEt表示乙氧基。
<10>.根据上述方法,其中,所述式2化合物选自如下结构的化合物中的至少一种:
Figure GDA0002414471660000032
其中,BOC表示叔丁氧羰基,tBu表示叔丁基,ph表示苯基,Ac表示乙酸基,I表示碘、而Cbz表示苄氧羰基。
本发明提供的方法,是通过利用光照激发光催化剂发生电子跃迁,从而催化活性羧酸酯脱羧,并与含氮杂环化合物发生minisci反应引入氮杂环。与之前报道的通过minisci反应引入氮杂环的方法相比,本方法使用碘化钠代替有机金属催化剂,符合发展绿色环境友好化学的要求,底物范围以及官能团兼容性良好,具有很大的合成价值前景。
具体实施方式
在本发明中,除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
在本发明中,术语“光引发非金属催化”中的“非金属”是指催化体系中不使用金属比如金属铱,因而“光引发非金属催化”是指在催化体系中不使用金属比如金属铱的情况下发生的光引发催化作用。
Figure GDA0002414471660000041
本发明提供一种光催化活性羧酸酯脱羧引入氮杂环的方法,反应过程如上述示意式 显示。
式1表示含氮杂环通式,包括被各种取代基取代或不被取代的喹啉、异喹啉、烟酸或菲啶,其取代基为C1-C30烷基、C6-C30芳基、卤素(例如,氟、氯、溴、碘)、甲基醚或酯基。
本发明的含氮杂环化合物中,上述C1-C30烷基包括直链或支链的 C1-C30烷基,其具体实例包括,例如,甲基、乙基、丙基、叔丁基、辛基、癸基、十二烷基、二十烷基、十八烷基、二十二烷基、三十烷基、等等。
本发明的含氮杂环化合物中,上述C6-C30芳基的具体实例包括,例如,苯基、甲基苯基、萘基、等等。
式2表示活性羧酸酯,并且式2和式3中的R为可以被取代基取代或不被取代的直链或支链烷基,或者是可以被取代基取代或不被取代的芳基基团,且R的碳原子数为1-30,优选1-20,更优选1-10,并且R的取代基的实例包括卤素原子(例如,氟、氯、溴、碘)、氨基、酯基、酰基、等等。
具体地,R为C1-C30的不含官能团的烷基(例如,甲基、乙基、丙基、叔丁基、辛基、癸基、十二烷基、二十烷基、十八烷基、二十二烷基、三十烷基、等等)、C1-C30的含官能团的烷基(例如,氯甲基、氯乙基、溴代十二烷基、等等)、C6-C30芳基(例如,苯基、甲基苯基、萘基、等等)或C5-C30杂芳基(例如,噻吩基、吡啶基、吡咯基、甲基吡啶基、等等)。
适用于本发明中的式1含氮杂环的具体实例包括:喹啉、异喹啉、 4-甲基喹啉、菲啶、4-乙氧基喹啉。
特别优选地,适用于本发明的所述式1化合物选自如下结构的化合物中的至少一种:
Figure GDA0002414471660000051
其中ph表示苯基,Br表示溴,而OEt表示乙氧基。
式2所表示的活性羧酸酯的具体实例包括在下面实施例部分的表1 中式1所示化学结构的化合物。例如,包括1,3-二氧代异吲哚啉-2-基环己烷羧酸酯、1,3-二氧代异吲哚啉-2-基-2,3-二氢苯并[b][1,4]二恶英-2- 羧酸酯、1,3-二氧代异吲哚啉-2-基-2-(3-氯苯氧基)丙酸酯、1,3-二氧代异吲哚啉-2-基-2-乙酰氨基-3-苯基丙酸酯、5-(叔丁基)-1-(1,3-二氧代异吲哚啉-2-基)((苄氧基)羰基)谷氨酸、等等。
特别优选地,适用于本发明的所述式2化合物选自如下结构的化合物中的至少一种:
Figure GDA0002414471660000061
其中,BOC表示叔丁氧羰基,tBu表示叔丁基,ph表示苯基,Ac表示乙酸基,I表示碘、而Cbz表示苄氧羰基。
本发明人发现,所述的活性羧酸酯脱羧反应转化当中,合理的式2 与式1的摩尔用量比,碘盐与式1的摩尔用量比、膦配体与式1的摩尔用量比,酸的种类及用量,以及光源的种类等是进行该反应最为重要的工艺条件,具体地如下:
所述的式2和式1的摩尔比为1.0-3.0,更优选为1.1-2.0。
所述简单的碘盐选自碘化钠、碘化钾以及碘化锂中的至少一种,更优选为碘化钠;碘盐的摩尔用量为所述式1的摩尔用量的5%-50%,更优选为5%-30%。
所述的膦配体选自三苯基膦、三(4-甲氧基苯基)膦、三(4-氟苯基)膦、三环己基膦、2-二苯基膦-联苯、4,5-双二苯基膦-9,9-二甲基氧杂蒽以及双(2-二苯基磷苯基)醚中的至少一种,更优选为三苯基膦。
膦配体的摩尔用量为所述式1的摩尔用量的5%-50%,更优选为 10-20%。
适合本发明使用的酸优选为三氟乙酸和R-联萘酚磷酸酯的一种,其中,且当采用三氟乙酸时,其摩尔用量为所述式1的摩尔用量的50%-150%,更优选为100%-110%。当采用R-联萘酚磷酸酯时,其摩尔用量为所述式1的摩尔用量的5%-50%,更优选为5%-20%。
在本发明的实施方案中,所述光源的波长范围优选为365nm到 500nm之间,更优选为440-456nm。照射时间为4小时至24小时,更优选为10-20小时。
在本发明的实施方案中,所述有机溶剂选自N,N-二甲基甲酰胺、 N,N-二甲基乙酰胺、乙腈、四氢呋喃、三氟甲苯、甲苯、丙酮、二氯甲烷以及乙酸乙酯中的至少一种,更优选为丙酮。
实施例
为了进一步阐明本发明,下面结合实施例对本发明优选实施方案进行描述,但是应当理解,这些描述只是为了进一步说明本发明的特征和优点,而不是对本发明权利要求的限制,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明下述实施例中用于光催化活性羧酸酯脱羧引入氮杂环所使用到的药品分别在以下试剂公司购买:
乙腈(C2H3N,99.9%),N,N-二甲基甲酰胺(C3H7NO,99.5%), N,N-二甲基乙酰胺(C4H9NO,99.0%),丙酮(C3H6O,99.5%)均从百灵威公司购买,四氢呋喃(C4H8O,99.5%),二氯甲烷(CH2Cl2, 99.9%),乙酸乙酯(C4H8O2,99.8%),三氟甲苯(C7H5F3,99%) 从安耐吉公司购买。
碘化钠(NaI,99.5%)和碘化钾从阿拉丁公司购买,三苯基膦(PPh3, 99%)从阿达马斯公司购买,三(4-甲氧基苯基)膦(C21H21O3P,95%),三(4-氟苯基)膦(C18H12F3P,98%),三环己基膦(C18H33P,96%), 2-二苯基膦-联苯(C24H19P,98%),4,5-双二苯基膦-9,9-二甲基氧杂蒽 (C39H32OP2,98.0%),双(2-二苯基磷苯基)醚(C36H28OP2,98%)和 (R)-联萘酚磷酸酯均从百灵威公司购买。
实施例1、制备2-环己基-4-甲基喹啉
反应式:
Figure GDA0002414471660000081
(其中Cy表示环己基)
具体方法如下:
在10mL的Schlenk反应管(北京欣维尔玻璃仪器有限公司, F891410反应管,容量10mL,磨口14/20)中加入NaI(0.02mmol(即,为含氮杂环化合物1a的10mol%。以下相同),3mg)、PPh3(0.04mmol (即,为含氮杂环化合物1a的20mol%。以下相同),10.5mg)和1,3- 二氧代异吲哚啉-2-基环己烷羧酸酯(2a,0.3mmol,81.9mg)。用氩气完全置换管内空气三次,然后在氩气氛围下加2mL丙酮、三氟乙酸 (0.2mmol,22.8mg)、4-甲基喹啉(1a,0.2mmol,28.6mg)。该反应体系在蓝光LED灯照射下室温下连续搅拌15小时(使用IKA磁力搅拌器,RCT基本型,搅拌速度500转/分钟)。反应完毕后,用 H2O淬灭反应,并用乙酸乙酯(3*10mL)萃取反应液,再将合并的有机相用旋转蒸发的方式浓缩(瑞士步琦有限公司,BUCHI旋转蒸发仪R-3)。浓缩残渣通过色谱柱(北京欣维尔玻璃仪器有限公司,C383040C 具砂板存储球层析柱,35/20,
Figure GDA0002414471660000082
有效长:500ml)层析分离得到产物。(产物为无色液体,共42.8毫克,产率95%,洗脱剂乙酸乙酯∶石油醚=1∶10~1∶5)。
1H NMR(400MHz,CDCl3)δ8.06(d,J=8.4Hz,1H),7.94(d,J=8.3 Hz,1H),7.66(ddd,J=8.3,6.9,1.3Hz,1H),7.53-7.46(m,1H),7.17(s,1H), 2.88(tt,J=12.1,3.3Hz,1H),2.68(s,3H),2.01(dd,J=13.2,1.7Hz,2H), 1.94-1.85(m,2H),1.83-1.76(m,1H),1.62(qd,J=12.4,2.9Hz,2H),1.54 -1.41(m,2H),1.39-1.30(m,1H)。
13C NMR(101MHz,CDCl3)δ166.5,147.5,144.4,129.4,129.0,127.0, 125.4,123.6,120.2,47.6,32.8,26.56,26.1,18.9。
实施例2、制备4-甲基-2-(戊-2-基)喹啉
反应式:
Figure GDA0002414471660000091
具体方法如下:
在10mL的Schlenk反应管(北京欣维尔玻璃仪器有限公司, F891410反应管,容量10mL,磨口14/20)中加入NaI(10mol%,3 mg)、PPh3(20mol%,10.5mg)和1,3-二氧代异吲哚啉-2-基2-甲基戊酸酯(0.3mmol,78.3mg)。用氩气完全置换管内空气三次,然后在氩气氛围下加2mL乙腈、三氟乙酸(0.2mmol,22.8mg)、4-甲基喹啉(0.2mmol,28.6mg)。该反应体系在蓝光LED灯照射下室温下连续搅拌17小时(使用IKA磁力搅拌器,RCT基本型,搅拌速度500转/分钟)。反应完毕后,用H2O淬灭反应,并用乙酸乙酯(3*10mL) 萃取反应液,再将合并的有机相用旋转蒸发的方式浓缩(瑞士步琦有限公司,BUCHI旋转蒸发仪R-3)。浓缩残渣通过色谱柱(北京欣维尔玻璃仪器有限公司,C383040C具砂板存储球层析柱,35/20,
Figure GDA0002414471660000092
有效长:500ml)层析分离得到产物。(产物为无色液体,共37.5毫克,产率88%,洗脱剂乙酸乙酯∶石油醚=1∶10~1∶5)。
1H NMR(400MHz,CDCl3)δ8.06(d,J=8.4Hz,1H),7.98-7.89(m, 1H),7.70-7.60(m,1H),7.53-7.43(m,1H),7.13(s,1H),3.19-2.97(m, 1H),2.67(s,3H),1.91-1.74(m,1H),1.71-1.58(m,1H),1.44-1.31(m, 4H),1.29-1.15(m,1H),0.89(t,J=7.3Hz,3H)。
13C NMR(101MHz,CDCl3)δ166.9,147.6,144.2,129.5,128.9,127.0, 125.4,123.6,120.2,42.7,39.3,20.9,20.7,18.8,14.2。
HRMS(ESI),C15H20N+[M+H]+的计算值:214.1590,测定值: 214.1587。
实施例3、制备2-(2,3-二氢苯并[b][1,4]二氧杂环己烯-2-基)-4-甲基喹啉
反应式:
Figure GDA0002414471660000101
具体方法如下:
在10mL的Schlenk反应管(北京欣维尔玻璃仪器有限公司, F891410反应管,容量10mL,磨口14/20)中加入NaI(20mol%,6 mg)、PPh3(20mol%,10.5mg)和1,3-二氧代异吲哚啉-2-基2,3-二氢苯并[b][1,4]二恶英-2-羧酸酯(0.3mmol,97.5mg)。用氩气完全置换管内空气三次,然后在氩气氛围下加2mL N,N-二甲基乙酰胺、三氟乙酸(0.2mmol,22.8mg)、4-甲基喹啉(0.2mmol,28.6mg)。该反应体系在蓝光LED灯照射下室温下连续搅拌17小时(使用IKA 磁力搅拌器,RCT基本型,搅拌速度500转/分钟)。反应完毕后,用 H2O淬灭反应,并用乙酸乙酯(3*10mL)萃取反应液,再将合并的有机相用旋转蒸发的方式浓缩(瑞士步琦有限公司,BUCHI旋转蒸发仪 R-3)。浓缩残渣通过色谱柱(北京欣维尔玻璃仪器有限公司,C383040C 具砂板存储球层析柱,35/20,
Figure GDA0002414471660000102
有效长:500ml)层析分离得到产物。(产物为粘稠液体,共47.7毫克,产率86%,洗脱剂乙酸乙酯∶石油醚=1∶10~1∶5)。
1H NMR(400MHz,CDCl3)δ8.08(d,J=8.4Hz,1H),7.99(d,J=8.4 Hz,1H),7.76-7.67(m,1H),7.60-7.54(m,1H),7.52(s,1H),7.11-7.04 (m,1H),6.98-6.87(m,3H),5.42(dd,J=8.0,2.6Hz,1H),4.71(dd,J=11.4, 2.6Hz,1H),4.48-4.06(m,1H),2.72(d,J=0.9Hz,3H)。
13C NMR(101MHz,CDCl3)δ156.4,147.3,145.8,143.5,143.3,129.7, 129.6,127.8,126.6,123.8,121.7,121.7,119.1,117.5,117.4,76.0,68.0,19.1。
HRMS(ESI),C18H16NO2 +[M+H]+的计算值:278.1176,测定值: 278.1176。
实施例4、制备2-(1-(3-氯苯氧基)乙基)-4-甲基喹啉
反应式:
Figure GDA0002414471660000111
具体方法如下:
在10mL的Schlenk反应管(北京欣维尔玻璃仪器有限公司, F891410反应管,容量10mL,磨口14/20)中加入KI(20mol%,6.7 mg)、PPh3(10mol%,5.3mg)和1,3-二氧代异吲哚啉-2-基-2-(3- 氯苯氧基)丙酸酯(0.3mmol,104.5mg)。用氩气完全置换管内空气三次,然后在氩气氛围下加2mL三氟甲苯、三氟乙酸(0.2mmol,22.8 mg)、4-甲基喹啉(0.2mmol,28.6mg)。该反应体系在蓝光LED灯照射下室温下连续搅拌21小时(使用IKA磁力搅拌器,RCT基本型,搅拌速度500转/分钟)。反应完毕后,用H2O淬灭反应,并用乙酸乙酯(3*10mL)萃取反应液,再将合并的有机相用旋转蒸发的方式浓缩 (瑞士步琦有限公司,BUCHI旋转蒸发仪R-3)。浓缩残渣通过色谱柱(北京欣维尔玻璃仪器有限公司,C383040C具砂板存储球层析柱, 35/20,
Figure GDA0002414471660000112
有效长:500ml)层析分离得到产物。(产物为白色固体,共48.7毫克,产率82%,洗脱剂乙酸乙酯∶石油醚=1∶10~1∶5)。
1H NMR(400MHz,CDCl3)δ8.11(d,J=8.4Hz,1H),7.95(d,J=8.3 Hz,1H),7.78-7.63(m,1H),7.61-7.48(m,1H),7.39(s,1H),7.11-7.03 (m,1H),6.98(t,J=2.1Hz,1H),6.89-6.76(m,2H),5.53(q,J=6.6Hz,1H), 2.66(s,3H),1.73(d,J=6.6Hz,3H)。
13C NMR(101MHz,CDCl3)δ162.0,158.6,146.9,146.2,134.8,130.2, 129.6,129.2,127.7,126.4,123.8,121.1,118.0,116.5,113.6,77.8,22.7,19.1。
HRMS(ESI),C18H17ONCl+[M+H]+的计算值:298.0993,测定值: 298.0987。
实施例5、制备2-(环己-3-烯-1-基)-4-甲基喹啉
反应式:
Figure GDA0002414471660000121
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.06(d,J=8.4Hz,1H),8.00-7.91(m, 1H),7.72-7.62(m,1H),7.55-7.45(m,1H),7.17(s,1H),5.98-5.69(m, 2H),3.21-3.09(m,1H),2.68(d,J=0.6Hz,3H),2.46-2.19(m,4H),2.11- 2.03(m,1H),2.00-1.86(m,1H)。
13C NMR(101MHz,CDCl3)δ165.9,147.5,144.5,129.5,129.1,127.0, 126.9,126.4,125.5,123.6,120.4,43.1,31.4,28.6,25.7,18.9。
HRMS(ESI),C16H18N+[M+H]+的计算值:224.1434,测定值:224.1428。
实施例6、制备2-(叔丁基)-4-甲基喹啉
反应式:
Figure GDA0002414471660000122
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.06(d,J=8.4Hz,1H),7.92(dd,J=8.3, 1.0Hz,1H),7.71-7.60(m,1H),7.55-7.42(m,1H),7.34(s,1H),2.67(s, 3H),1.46(s,9H)。
13C NMR(101MHz,CDCl3)δ168.9,147.2,143.7,129.9,128.8,126.6, 125.5,123.4,118.9,37.9,30.2,19.0。
实施例7、制备2-(5-(2,5-二甲基苯氧基)-2-甲基戊-2-基)-4-甲基喹啉
反应式:
Figure GDA0002414471660000131
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.11(d,J=7.4Hz,1H),8.02-7.92(m, 1H),7.76-7.64(m,1H),7.60-7.49(m,1H),7.37(s,1H),7.02(d,J=7.5 Hz,1H),6.66(d,J=7.5Hz,1H),6.55(s,1H),3.88(t,J=6.4Hz,2H),2.70 (d,J=0.7Hz,3H),2.29(s,3H),2.21(s,3H),2.10-2.00(m,2H),1.73- 1.63(m,2H),1.53(s,6H)。
13C NMR(101MHz,CDCl3)δ167.6,157.0,147.2,143.6,136.4,130.2, 129.9,128.7,126.5,125.5,123.4,120.4,119.2,111.8,68.1,40.8,39.4,28.0, 25.1,21.4,19.0,15.8。
HRMS(ESI),C24H30NO+[M+H]+的计算值:348.2322,测定值: 348.2316。
实施例8、制备4-甲基-4-(4-甲基喹啉-2-基)哌啶-1-羧酸叔丁酯
反应式:
Figure GDA0002414471660000132
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.03(d,J=8.3Hz,1H),7.94(d,J=8.3 Hz,1H),7.73-7.61(m,1H),7.56-7.47(m,1H),7.27(s,1H),3.88-3.60 (m,2H),3.37-3.09(m,2H),2.68(s,3H),2.60-2.38(m,2H),1.89-1.64 (m,2H),1.45(s,9H),1.33(s,3H)。
13C NMR(101MHz,CDCl3)δ165.9,155.1,147.4,144.2,129.9,128.9, 126.6,125.8,123.5,119.1,79.1,39.8,36.2,29.0,28.5,19.1。
HRMS(ESI),C21H29N2O2 +[M+H]+的计算值:341.2224,测定值: 341.2218。
实施例9、制备2-金刚烷基-4-甲基喹啉
反应式:
Figure GDA0002414471660000141
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.06(d,J=8.3Hz,1H),7.92(dd,J=8.3, 0.9Hz,1H),7.71-7.58(m,1H),7.53-7.43(m,1H),7.32(s,1H),2.67(s, 3H),2.21-2.07(m,9H),1.90-1.74(m,6H)。
13C NMR(101MHz,CDCl3)δ168.7,147.6,143.6,123.0,128.7,126.7, 125.4,123.4,118.5,41.8,39.6,36.9,28.9,19.0。
实施例10、制备(1-(5-甲基喹啉-2-基)-3-(甲硫基)丙基)氨基甲酸叔丁酯
反应式:
Figure GDA0002414471660000142
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.05(d,J=8.3Hz,1H),7.95(dd,J= 8.4,0.9Hz,1H),7.75-7.63(m,1H),7.60-7.46(m,1H),7.19(s,1H),6.20 (d,J=7.3Hz,1H),5.01(dd,J=13.4,6.7Hz,1H),2.68(s,3H),2.60-2.50 (m,1H),2.45-2.35(m,1H),2.33-2.19(m,1H),2.17-2.07(m,1H),2.07 (s,3H),1.46(s,9H)。
13C NMR(101MHz,CDCl3)δ159.6,155.6,147.2,145.1,129.6,129.3, 127.4,126.1,123.7,120.7,79.3,54.7,36.1,30.1,28.4,18.8,15.5。
HRMS(ESI),C19H27N2O2S+[M+H]+的计算值:347.1788,测定值: 347.1782。
实施例11、制备(2-(4-(叔丁氧基)苯基)-1-(4-甲基喹啉-2-基) 乙基)氨基甲酸叔丁酯
反应式:
Figure GDA0002414471660000151
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.05(d,J=7.5Hz,1H),7.93(d,J= 8.1Hz,1H),7.69(t,J=7.6Hz,1H),7.53(t,J=7.5Hz,1H),6.92-6.77(m, 4H),6.73(s,1H),6.20(br,1H),5.05(dd,J=13.5,7.4Hz,1H),3.40-2.96 (m,2H),2.55(s,3H),1.45(s,9H),1.29(s,9H)。
13C NMR(101MHz,CDCl3)δ159.4,155.3,153.7,147.2,144.0,132.5, 130.0,129.6,129.1,127.3,126.0,124.0,123.7,121.4,79.2,78.2,57.1,42.3, 28.8,28.5,18.7。
HRMS(ESI),C27H35N2O3 +[M+H]+的计算值:435.2642,测定值: 435.2632。
实施例12、制备(1-(4-甲基喹啉-2-基)环丁基)氨基甲酸叔丁酯
反应式:
Figure GDA0002414471660000152
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.09(d,J=8.4Hz,1H),8.02-7.90(m, 1H),7.74-7.62(m,1H),7.57-7.45(m,2H),6.40(br,1H),3.14-2.54(m, 7H),2.31-1.92(m,2H),1.47(s,9H)。
13C NMR(101MHz,CDCl3)δ163.4,154.9,146.6,145.1,129.8,129.1, 127.1,125.9,123.5,118.4,79.1,59.7,33.5,28.5,19.1,14.6。
HRMS(ESI),C19H25N2O2 +[M+H]+的计算值:313.1911,测定值: 313.1905。
实施例13、制备2-(1-(4-甲基喹啉-2-基)-2-苯基乙基)异吲哚-1,3- 二酮
反应式:
Figure GDA0002414471660000161
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.08(d,J=8.3Hz,1H),7.97-7.89(m, 1H),7.78-7.73(m,2H),7.70-7.62(m,3H),7.55-7.48(m,1H),7.38- 7.29(m,3H),7.23-7.16(m,2H),7.15-7.08(m,1H),5.96(dd,J=10.8,5.9 Hz,1H),4.18-3.84(m,2H),2.65(d,J=0.8Hz,3H)。
13C NMR(101 MHz,CDCl3)δ168.4,157.7,147.3,145.2,138.1,133.9, 131.8,130.1,129.3,129.1,128.5,127.4,126.6,126.4,123.6,123.3,119.8, 57.6,36.2,19.0。
HRMS(ESI),C26H21N2O2 +[M+H]+的计算值:393.1598,测定值: 393.1590。
实施例14、制备N-(1-(4-甲基喹啉-2-基)乙基)苯甲酰胺
反应式:
Figure GDA0002414471660000162
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.43(d,J=6.2Hz,1H),8.10(d,J=8.1 Hz,1H),8.02-7.91(m,3H),7.75-7.68(m,1H),7.60-7.44(m,4H),7.23 (s,1H),5.41(p,J=6.7Hz,1H),2.71(s,3H),1.67(d,J=6.8Hz,3H)。
13C NMR(101MHz,CDCl3)δ166.6,160.5,146.8,145.5,134.9,131.4,129.5,128.5,127.5,127.1,126.2,123.8,120.3,50.3,22.7,18.9。
HRMS(ESI),C19H19N2O+[M+H]+的计算值:291.1492,测定值: 291.1485。
实施例15、制备(2-(4-碘苯基)-1-(4-甲基喹啉-2-基)乙基)氨基甲酸叔丁酯
反应式:
Figure GDA0002414471660000171
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.05(d,J=8.3Hz,1H),7.95(dd,J =8.3,0.9Hz,1H),7.76-7.64(m,1H),7.54(ddd,J=8.2,6.9,1.2Hz,1H), 7.48(d,J=8.0Hz,2H),6.87(s,1H),6.74(d,J=7.9Hz,2H),6.14(s,1H), 5.06(dd,J=13.6,7.1Hz,1H),3.35-3.06(m,2H),2.61(s,3H),1.44(s, 9H)。
13C NMR(101MHz,CDCl3)δ158.9,155.3,147.2,144.7,137.2,137.1,131.8,129.6,129.4,127.4,126.2,123.8,121.2,91.8,79.4,56.6,42.0,28.4, 18.7。
HRMS(ESI),C23H26N2O2I+[M+H]+的计算值:489.1033,测定值: 489.1024。
实施例16、制备4-甲基-2-(1-苯基环丙基)喹啉酮
反应式:
Figure GDA0002414471660000172
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.02(d,J=7.9Hz,1H),7.87(dd,J=8.3,1.0Hz,1H),7.64(ddd,J=8.4,6.9,1.4Hz,1H),7.48-7.39(m,3H),7.37- 7.32(m,2H),7.30-7.24(m,1H),6.94(d,J=0.9Hz,1H),2.52(s,3H),1.82 (q,J=3.8Hz,2H),1.35(q,J=3.8Hz,2H)。
13C NMR(101MHz,CDCl3)δ163.7,147.5,143.7,143.5,130.1,129.5, 129.0,128.5,126.6,126.5,125.3,123.5,121.9,32.1,18.7,17.2。
HRMS(ESI),C19H18N+[M+H]+的计算值:260.1434,测定值:260.1429。
实施例17、制备(2-(叔丁氧基)-1-(4-甲基喹啉-2-基)乙基)氨基甲酸叔丁酯
反应式:
Figure GDA0002414471660000181
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.06(d,J=8.3Hz,1H),7.96(d,J=8.3 Hz,1H),7.67(t,J=7.2Hz,1H),7.52(t,J=7.3Hz,1H),7.31(s,1H),6.13 (d,J=5.4Hz,1H),5.08-4.81(m,1H),3.92-3.79(m,1H),3.72-3.53(m, 1H),2.69(s,3H),1.48(s,9H),1.07(s,9H)。
13C NMR(101MHz,CDCl3)δ159.3,155.6,147.2,144.0,129.5,129.0, 127.4,125.9,123.7,121.3,79.3,73.3,64.7,56.1,28.4,27.4,18.8。
HRMS(ESI),C21H31N2O3 +[M+H]+的计算值:359.2329,测定值: 359.2322。
实施例18、制备4-(((苄氧基)羰基)氨基)-4-(4-甲基喹啉-2-基) 丁酸叔丁酯反应式:
Figure GDA0002414471660000182
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.03(d,J=8.3Hz,1H),7.99-7.90(m,1H),7.72-7.63(m,1H),7.60-7.49(m,1H),7.42-7.30(m,5H),7.19(s, 1H),6.60(d,J=7.4Hz,1H),5.24-4.95(m,3H),2.61(d,J=54.4Hz,3H), 2.45-2.26(m,2H),2.26-2.00(m,2H),1.39(s,9H)。
13C NMR(101MHz,CDCl3)δ172.6,159.1,156.1,147.0,145.2,136.6, 129.5,129.3,128.5,128.1,128.1,127.4,126.2,123.7,120.4,80.3,66.7,55.1, 31.4,31.3,28.0,18.8。
HRMS(ESI),C26H31N2O4 +[M+H]+的计算值:435.2278,测定值: 435.2271。
实施例19、制备(3-(甲硫基)-1-(4-苯基喹啉-2-基)丙基)氨基甲酸叔丁酯
反应式:
Figure GDA0002414471660000191
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.14(d,J=8.0Hz,1H),7.90(d,J=8.3 Hz,1H),7.72(t,J=7.5Hz,1H),7.56-7.45(m,6H),7.31(s,1H),6.21(d,J= 5.0Hz,1H),5.24-4.92(m,1H),2.65-2.44(m,2H),2.37-2.12(m,2H), 2.08(s,3H),1.47(s,9H)。
13C NMR(101MHz,CDCl3)δ159.5,155.6,149.3,147.9,137.9,129.5, 129.4,128.6,128.6,126.5,125.9,125.8,120.2,79.4,54.8,36.3,30.2,28.4, 15.5。
HRMS(ESI),C24H29N2O2S+[M+H]+的计算值:409.1944,测定值: 409.1937。
实施例20、制备4-环己基-2-甲基喹啉
反应式:
Figure GDA0002414471660000201
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.14-7.92(m,2H),7.82-7.59(m,1H), 7.56-7.45(m,1H),7.17(s,1H),3.41-3.16(m,1H),2.72(s,3H),2.10- 1.80(m,5H),1.64-1.46(m,4H),1.45-1.27(m,1H)。
13C NMR(101MHz,CDCl3)δ158.7,153.5,148.0,129.4,128.9,125.3, 125.2,122.8,118.3,38.8,33.6,26.9,26.3,25.4。
实施例21、制备1-环己基异喹啉
反应式:
Figure GDA0002414471660000202
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.48(d,J=5.7Hz,1H),8.23(d,J=8.4 Hz,1H),7.81(d,J=8.0Hz,1H),7.65(ddd,J=8.1,6.9,1.2Hz,1H),7.58 (ddd,J=8.2,6.9,1.3Hz,1H),7.48(d,J=5.7Hz,1H),3.57(tt,J=11.7,3.3 Hz,1H),2.04-1.76(m,7H),1.62-1.47(m,2H),1.46-1.37(m,1H)。
13C NMR(101MHz,CDCl3)δ165.7,141.8,136.4,129.6,127.6,126.8, 126.3,124.8,118.9,41.5,32.6,26.9,26.2。
实施例22、制备7-溴-1-环己基异喹啉
反应式:
Figure GDA0002414471660000203
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.48(d,J=5.7Hz,1H),8.07(d,J=9.1 Hz,1H),7.96(d,J=2.0Hz,1H),7.63(dd,J=9.0,2.0Hz,1H),7.37(d,J= 5.7Hz,1H),3.59-3.42(m,1H),2.07-1.89(m,4H),1.89-1.71(m,3H), 1.61-1.46(m,2H),1.44-1.33(m,1H)。
13C NMR(101MHz,CDCl3)δ166.0,143.0,137.6,130.3,129.6,126.6, 124.7,124.3,117.9,41.6,32.6,26.8,26.2。
HRMS(ESI),C15H17NBr+[M+H]+的计算值:290.0539,测定值: 290.0534。
实施例23、制备5-溴-1-环己基异喹啉
反应式:
Figure GDA0002414471660000211
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.58(d,J=6.0Hz,1H),8.20(d,J=8.7 Hz,1H),8.00-7.90(m,1H),7.91-7.81(m,1H),7.46-7.38(m,1H),3.68- 3.39(m,1H),2.05-1.90(m,4H),1.89-1.74(m,3H),1.61-1.45(m,2H), 1.45-1.35(m,1H)。
13C NMR(101MHz,CDCl3)δ165.0,142.2,134.5,132.3,126.4,126.0, 123.4,121.6,116.7,40.7,31.7,25.8,25.1。
HRMS(ESI)计算值for C15H17NBr+[M+H]+:290.0539。测定值: 290.0534。
实施例24、制备6-环己基菲啶
反应式:
Figure GDA0002414471660000212
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.59(d,J=8.3Hz,1H),8.54-8.42(m, 1H),8.28(d,J=8.3Hz,1H),8.14(d,J=8.0Hz,1H),7.84-7.72(m,1H), 7.70-7.60(m,2H),7.60-7.51(m,1H),3.68-3.32(m,1H),2.18-1.71(m, 7H),1.65-1.38(m,3H)。
13C NMR(101MHz,CDCl3)δ164.2,142.8,132.0,128.9,127.3,126.0, 125.1,124.6,123.7,122.3,121.5,120.8,40.9,31.2,25.8,25.3。
实施例25、制备2-(叔丁基)-4-乙氧基喹啉
反应式:
Figure GDA0002414471660000221
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ8.16(d,J=8.2Hz,1H),7.98(d,J=5.7 Hz,1H),7.64(t,J=7.4Hz,1H),7.42(t,J=7.4Hz,1H),6.82(s,1H),4.27 (q,J=6.9Hz,2H),1.57(t,J=6.9Hz,3H),1.46(s,9H)。
13C NMR(101MHz,CDCl3)δ170.5,161.5,148.4,129.4,128.8,124.7, 121.5,119.9,97.2,63.7,38.41,30.2,14.6。
HRMS(ESI),C15H20NO+[M+H]+的计算值:230.1539,测定值: 230.1535。
实施例26、制备3-(6-甲氧基-2-甲基喹啉-4-基)吗啉-4-羧酸叔丁酯
反应式:
Figure GDA0002414471660000222
方法同实施例1,产率见表1。
1H NMR(400MHz,CDCl3)δ7.97(d,J=9.2Hz,1H),7.44(s,1H),7.35(dd,J=9.2,2.5Hz,1H),7.23(s,1H),5.02(dd,J=10.2,2.1Hz,1H), 4.61-3.99(m,3H),3.96(s,3H),3.83(td,J=11.7,2.3Hz,1H),3.25-2.78 (m,2H),2.71(s,3H),1.50(s,9H)。
13C NMR(101MHz,CDCl3)δ157.3,156.3,154.5,143.8,142.9,134.1, 130.9,124.3,123.4,121.2,119.0,101.3,80.4,74.5,67.1,55.6,28.4,25.1。
HRMS(ESI),C20H27N2O4 +[M+H]+的计算值:359.1965,测定值:359.1959。
实施例27、制备6-(1-乙酰氨基-2-苯乙基)乙酸乙酯
反应式:
Figure GDA0002414471660000231
在10mL的Schlenk反应管(北京欣维尔玻璃仪器有限公司, F891410反应管,容量10mL,磨口14/20)中加入NaI(10mol%,3 mg)、PPh3(20mol%,10.5mg)、(R)-联萘酚磷酸酯(10mol%, 7.0mg)和1,3-二氧代异吲哚啉-2-基-2-乙酰氨基-3-苯基丙酸酯(0.26 mmol,91.5mg)。用氩气完全置换管内空气三次,然后在氩气氛围下加1,4-二氧六环2mL、烟酸乙酯(0.2mmol,30.3mg)。该反应体系在蓝光LED灯照射下室温下连续搅拌20小时(使用IKA磁力搅拌器, RCT基本型,搅拌速度500转/分钟)。反应完毕后,用H2O淬灭反应,并用乙酸乙酯(3*10mL)萃取反应液,再将合并的有机相用旋转蒸发的方式浓缩(瑞士步琦有限公司,BUCHI旋转蒸发仪R-3)。浓缩残渣通过色谱柱(北京欣维尔玻璃仪器有限公司,C383040C具砂板存储球层析柱,35/20,
Figure GDA0002414471660000232
有效长:500ml)层析分离得到产物。(产物为白色固体,共50毫克,产率80%,洗脱剂乙酸乙酯∶石油醚=1∶10~1∶5)。
1H NMR(400MHz,CDCl3)δ9.14(d,J=1.6Hz,1H),8.11(dd,J=8.1, 2.1Hz,1H),7.23-7.15(m,3H),6.97-6.87(m,4H),5.35(td,J=8.2,5.6 Hz,1H),4.40(q,J=7.1Hz,2H),3.27(dd,J=13.2,5.6Hz,1H),3.04(dd,J =13.2,8.4Hz,1H),2.03(s,3H),1.40(t,J=7.1Hz,3H)。
13C NMR(101MHz,CDCl3)δ169.5,165.0,163.0,150.3,137.4,136.7, 129.4,128.3,126.7,125.2,122.4,61.5,55.4,42.3,23.4,14.3。
HRMS(ESI),C18H21N2O3 +[M+H]+的计算值:313.1547,测定值: 313.1555。
实施例28、克级反应:制备4-(((苄氧基)羰基)氨基)-4-(4-甲基喹啉-2-基)丁酸叔丁酯
反应式:
Figure GDA0002414471660000241
在100mL的Schlenk反应管(北京欣维尔玻璃仪器有限公司, F891410反应管,容量100mL,磨口14/20)中加入NaI(5mol%,60 mg)、PPh3(5mol%,105mg)和5-(叔丁基)-1-(1,3-二氧代异吲哚啉-2-基)(苄氧羰基)谷氨酸(8.8mmol,4.3g)。用氩气完全置换管内空气三次,然后在氩气氛围下加40mL丙酮,三氟乙酸(8mmol,91.2 mg),4-甲基喹啉(8mmol,1.15g)。该反应体系在36W蓝光LED 灯照射下室温下连续搅拌15小时(使用IKA磁力搅拌器,RCT基本型,搅拌速度500转/分钟)。反应完毕后,用H2O淬灭反应,并用乙酸乙酯(3*20mL)萃取反应液,再将合并的有机相用旋转蒸发的方式浓缩(瑞士步琦有限公司,BUCHI旋转蒸发仪R-3)。浓缩残渣通过色谱柱(北京欣维尔玻璃仪器有限公司,C383040C具砂板存储球层析柱,35/20,
Figure GDA0002414471660000242
有效长:500ml)层析分离得到产物。(产物为无色液体,共2.785克,产率80%,洗脱剂乙酸乙酯∶石油醚=1∶10~1∶5)
1H NMR(400MHz,CDCl3)δ8.03(d,J=8.3Hz,1H),7.99-7.90(m, 1H),7.72-7.63(m,1H),7.60-7.49(m,1H),7.42-7.30(m,5H),7.19(s, 1H),6.60(d,J=7.4Hz,1H),5.24-4.95(m,3H),2.61(d,J=54.4Hz,3H),2.45-2.26(m,2H),2.26-2.00(m,2H),1.39(s,9H)。
13C NMR(101MHz,CDCl3)δ172.6,159.1,156.1,147.0,145.2,136.6,129.5,129.3,128.5,128.1,128.1,127.4,126.2,123.7,120.4,80.3,66.7,55.1, 31.4,31.3,28.0,18.8。
HRMS(ESI),C26H31N2O4 +[M+H]+的计算值:435.2278,测定值:435.2271。
表1氮杂环芳烃(式1)和活性羧酸酯(式2)反应得到式3化合物
Figure GDA0002414471660000251
Figure GDA0002414471660000261
Figure GDA0002414471660000271
工业可适用性
本发明提供的方法利用光催化,在室温下实现高效催化转化,反应条件温和,操作简单。与之前报道的传统方法相比,该方法避免了贵金属催化剂的使用,符合发展绿色环境友好化学的要求,底物范围广、官能团兼容性好,且该方法可以成功应用于克级规模的放大实验,反应的转化率高,具有工业合成价值前景。

Claims (10)

1.一种光诱导活性羧酸酯脱羧引入氮杂环的方法,所述方法包括以下步骤:
在简单的碘盐、膦配体、酸以及有机溶剂存在的条件下,通过光照实现式1含氮杂环化合物与式2化合物反应得到具有式3结构的化合物:
Figure FDA0002414471650000011
其中:
式1的含氮杂环化合物包括被各种取代基取代或不被取代的喹啉、异喹啉、烟酸或菲啶,并且所述各种取代基为C1-C30烷基、C6-C30芳基、卤素、甲基醚或酯基;
式2和式3中的R为不含官能团的C1-C30烷基、含官能团的C1-C30烷基、C6-C30芳基或C5-C30杂芳基,所述官能团为选自卤素、酯基、醚基、酰基、磺酰基、巯基和氨基中的至少一种,
其中所述简单的碘盐选自碘化钠、碘化钾以及碘化锂中的至少一种。
2.根据权利要求1所述的方法,其中,所述式2化合物和式1含氮杂环化合物的摩尔比为1.0-3.0。
3.根据权利要求1所述的方法,其中,所述碘盐的摩尔用量为所述含氮杂环化合物摩尔用量的5%-50%。
4.根据权利要求1所述的方法,其中,所述的膦配体选自三苯基膦、三(4-甲氧基苯基)膦、三(4-氟苯基)膦、三环己基膦、2-二苯基膦-联苯、4,5-双二苯基膦-9,9-二甲基氧杂蒽以及双(2-二苯基磷苯基)醚中的至少一种。
5.根据权利要求1所述的方法,其中,膦配体的摩尔用量为所述式1含氮杂环化合物的摩尔用量的5%-50%。
6.根据权利要求1所述的方法,其特征在于,所述的酸为三氟乙酸和(R)-联萘酚磷酸酯的一种,且当采用三氟乙酸时,其摩尔用量为所述式1含氮杂环化合物的摩尔用量的50%-150%;当采用(R)-联萘酚磷酸酯时,其摩尔用量为所述式1含氮杂环化合物的摩尔用量的5%-50%。
7.根据权利要求1所述的方法,其中,所述光源的波长范围为365nm到500nm之间,照射时间为4小时至24小时。
8.根据权利要求1所述的方法,其中,所述有机溶剂选自N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、乙腈、四氢呋喃、三氟甲苯、甲苯、丙酮、二氯甲烷和乙酸乙酯中的至少一种。
9.根据权利要求1所述的方法,其中,所述式1化合物选自如下结构的化合物中的至少一种:
Figure FDA0002414471650000021
其中ph表示苯基,Br表示溴,而OEt表示乙氧基。
10.根据权利要求1所述的方法,其中,所述式2化合物选自如下结构的化合物中的至少一种:
Figure FDA0002414471650000022
Figure FDA0002414471650000031
其中,BOC表示叔丁氧羰基,tBu表示叔丁基,ph表示苯基,Ac表示乙酸基,I表示碘、而Cbz表示苄氧羰基。
CN201811145402.5A 2018-09-26 2018-09-26 一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法 Active CN109134362B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201811145402.5A CN109134362B (zh) 2018-09-26 2018-09-26 一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法
PCT/CN2019/106182 WO2020063399A1 (zh) 2018-09-26 2019-09-17 一种光诱导非金属催化活性羧酸酯脱羧偶联的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811145402.5A CN109134362B (zh) 2018-09-26 2018-09-26 一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法

Publications (2)

Publication Number Publication Date
CN109134362A CN109134362A (zh) 2019-01-04
CN109134362B true CN109134362B (zh) 2020-08-25

Family

ID=64813363

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811145402.5A Active CN109134362B (zh) 2018-09-26 2018-09-26 一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法

Country Status (1)

Country Link
CN (1) CN109134362B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020063399A1 (zh) * 2018-09-26 2020-04-02 中国科学技术大学 一种光诱导非金属催化活性羧酸酯脱羧偶联的方法
CN112174899B (zh) * 2019-07-01 2023-01-17 南开大学 光促进的Minisci C-H烷基化反应在制备烷基取代的氮杂环中的应用
CN111269133B (zh) * 2020-03-10 2021-04-23 中国科学技术大学 光诱导阴离子催化的非天然氨基酸的合成方法
CN111233752B (zh) * 2020-03-10 2021-07-09 中国科学技术大学 烷基活性羧酸酯脱羧原位甲基化的方法
CN113620934B (zh) * 2021-08-16 2023-07-07 南京先进生物材料与过程装备研究院有限公司 一种可见光介导的微反应装置中含氮杂环化合物烷基化方法
CN114085187A (zh) * 2021-11-16 2022-02-25 中国科学技术大学 光诱导烷基活性羧酸酯脱羧烷基化的方法
CN114478609B (zh) * 2022-01-24 2023-06-16 中国科学技术大学 硫酚光催化剂用于脱氟烷基化或脱氟质子化反应的方法
CN114989089A (zh) * 2022-07-18 2022-09-02 河南师范大学 一种3-烷基-2-苯基吲唑类化合物的光催化制备方法
CN115626889B (zh) * 2022-10-17 2024-04-30 南京工业大学 一种含氮杂环化合物氧化脱氢的有机化学转化方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496114B (zh) * 2016-10-18 2019-11-22 中国科学技术大学 一种芳香氮杂环化合物的制备方法

Also Published As

Publication number Publication date
CN109134362A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
CN109134362B (zh) 一种光诱导非金属催化活性羧酸酯脱羧引入氮杂环的方法
Molander et al. Reductive cross-coupling of nonaromatic, heterocyclic bromides with aryl and heteroaryl bromides
Bagley et al. Synthesis of tetrasubstituted pyridines by the acid-catalysed Bohlmann–Rahtz reaction
CN109180576B (zh) 一种光诱导非金属对映选择性催化杂环芳烃minisci反应的方法
Wang et al. Selective synthesis of quaternary carbon propargylamines from amines, alkynes, and alkynes under neat condition
CN109096150B (zh) 一种光诱导非金属催化制备β-氨基酮的方法
Alcaide et al. Accessing skeletal diversity under iron catalysis using substrate control: Formation of pyrroles versus lactones
Guizzetti et al. Chiral Lewis base promoted trichlorosilane reduction of ketimines. An enantioselective organocatalytic synthesis of chiral amines
Zhong et al. Benzylic C–H heteroarylation of N-(benzyloxy) phthalimides with cyanopyridines enabled by photoredox 1, 2-hydrogen atom transfer
JP2013170151A (ja) インドール‐3−トリフロン類の直接的製造法及びインドールトリフロン誘導体
Sun et al. One-pot and divergent synthesis of furo [3, 2-c] quinolines and quinazolin-4 (3H)-ones via sequential isocyanide-based three-component/Staudinger/aza-Wittig reaction
Bartoli et al. The CeCl3· 7H2O–NaI system as promoter in the synthesis of functionalized trisubstituted alkenes via Knoevenagel condensation
Zhang et al. Regioselective deoxygenative CH trifluoromethylthiolation of heteroaryl N-oxides with AgSCF3
Pei et al. Quinidine derived organocatalysts for the nucleophile promoted asymmetric [4+ 2] cycloaddition reaction of salicyl N-tosylimine with allenic esters
Endo et al. Stereo-defined synthesis of differentially all-carbon tetrasubstituted alkenes derived from (E)-1-bromo-2-iodoalkenes
Ma et al. Facile synthesis of 3-arylpyridine derivatives by palladacycle-catalyzed Stille cross-coupling reaction
WO2020063399A1 (zh) 一种光诱导非金属催化活性羧酸酯脱羧偶联的方法
CA2399089C (en) Process for exchanging functional groups by halogen-metal exchange reaction
Wang et al. An approach to 1-phosphorylated isoquinolines through silver (I)-catalyzed tandem reaction involving C–N and C–P bond formation
Xu et al. The Synthesis of N‐Arylated Amides via Copper (II) Triflate‐Catalyzed Direct Oxygenation and N‐Arylation of Benzylamines with Aryl Iodides
CN108026032B (zh) 光学活性4-氨基甲酰基-2,6-二甲基苯基丙氨酸衍生物的制造方法
US20080194825A1 (en) Process for obtaining montelukast
JP2017144424A (ja) 触媒、アミド結合の形成方法、及びアミド化合物の製造方法
CN111018691A (zh) 一种芳香酸的绿色合成方法
KR20190083292A (ko) 유기금속 이리듐 착물, 이의 합성 방법 및 이를 이용한 유기 발광 디바이스

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant